Health Care · Pharmaceutical Preparations · Nasdaq · CIK 897448 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $14.16Day +1.51%Mkt cap $5.3B1Y −3.3%Off 52W high −32.2%Vol (1Y) 45.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.1% of sh out |
| Days to cover6.4d |
| 13F net flow (QoQ)+0.08% |
| Top-10 13F concentration90.4% |
| Next report (est.)2026-07-29 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$187.2M |
| Earnings (TTM)-$27.1M |
| ROE−8.2% |
| Net margin−18.1% |
| ROIC−22.7% |
| Sales growth 3Y−16.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+1.4% |
| 1Y−3.3% |
| 3Y−41.0% |
| 5Y−83.3% |
| 10Y−73.3% |
| Since incept. (ann.)−13.0% |
Total return through 2026-07-29 · series begins 2005-07-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)45.1% |
| Ann. volatility (3Y)65.4% |
| Sharpe (1Y)0.09 |
| Sharpe (3Y)0.05 |
| Max drawdown (1Y)−33.3% |
| Max drawdown (3Y)−70.4% |
| Beta (3Y vs SPY)0.95 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Sarissa Capital Management LP | 1.7M | $24M | 0.44% | +0.0% |
| ACADIAN ASSET MANAGEMENT LLC | 636,769 | $9M | 0.17% | +9.7% |
| Kynam Capital Management, LP | 472,382 | $7M | 0.12% | +21.3% |
| MILLENNIUM MANAGEMENT LLC | 300,536 | $4M | 0.08% | +80.8% |
| MORGAN STANLEY | 293,172 | $4M | 0.08% | −11.2% |
| Point72 Asset Management, L.P. | 240,761 | $3M | 0.06% | +559.8% |
| Waterfront Wealth Inc. | 203,338 | $3M | 0.05% | +42.7% |
| Eversept Partners, LP | 147,715 | $2M | 0.04% | −14.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | −$0.03 | — | $45.4M | +7.4% |
| 2025-12-31 | 2026-02-25 | — | — | $49.5M | −20.9% |
| 2025-09-30 | 2025-10-29 | −$0.02 | — | $49.9M | +17.3% |
| 2025-06-30 | 2025-07-30 | −$0.03 | — | $73.0M | +7.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-29 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 86% · Licensing And Royalty 14%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
